Development and Market Objectives

The final goal of the project is to develop Best-in-Class c-Met inhibitor for personalized medicine with ABN401 small molecule.

Unmet Medical Need & Target Patients

Unmet Medical Need:

- Low survival and high relapse

- 5Yr postoperative survival: 35%

  Survival with chemotherapy: 40%

- Local regional relapse: 87%

  Remote metastasis: 30%

- Hard to apply standard therapeutics after relapse

Target Patients:

- Gastric Cancer patients

Current Progress

- In vitro experiment to verify Mode of action

- Efficacy test compared to reference drug with Xenograft Model using gastric cancer cell line

- Efficacy test with Patient-Derived Xenograft (PDX) Model

Intellectual Property

- PCT application: Korea, China, Europe, Japan, India and USA

- Registration of patents are submitted

- New patents are under preparation

Competitive Advantages

- Currently, there is no FDA approved drug for the c-Met target.

- ABN 401 can be used as personalized treatment by c-Met specific inhibitor.

Disease Target

Oncology

Project duration

2016.8.1-2017.9.30

Organization

ABION. INC

Phase of Development

Optimization

Contact

• Organization: ABION. INC
• Website: http://www.abionbio.com
• Contact Person: Eun Jin Kim
• E-mail: ejkim@abionbio.com
• Phone No.: +82-2-6006-7615

Related Projects